Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

IDYA

Ideaya Biosciences Inc

Dec 01 • 04:00PM ET

31.63

Dollar change +0.18
Percentage change 0.57	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.95	Insider Own	13.82%	Shs Outstand	62.44M	Perf Week	-1.16%
Market Cap	1.97B	Forward P/E	-	EPS next Y	-2.34	Insider Trans	-0.50%	Shs Float	53.81M	Perf Month	9.48%
Income	-103.21M	PEG	-	EPS next Q	-0.50	Inst Own	83.76%	Short Float / Ratio	15.68% / 11.06	Perf Quarter	6.25%
Sales	23.48M	P/S	84.11	EPS this Y	-34.65%	Inst Trans	18.09%	Short Interest	8.44M	Perf Half Y	27.18%
Book/sh	8.67	P/B	3.65	EPS next Y	-22.42%	ROA	-21.87%	Target Price	37.45	Perf Year	76.90%
Cash/sh	7.51	P/C	4.21	EPS next 5Y	-	ROE	-23.54%	52W Range	13.29 - 33.24	Perf YTD	74.08%
Dividend	-	P/FCF	-	EPS past 5Y	-19.27%	ROI	-20.31%	52W High	-4.84%	Beta	0.80
Dividend %	-	Quick Ratio	19.37	Sales past 5Y	25.06%	Gross Margin	85.09%	52W Low	138.00%	ATR	1.42
Employees	103	Current Ratio	19.37	Sales Q/Q	-72.94%	Oper. Margin	-506.54%	RSI (14)	62.36	Volatility	4.57% 4.40%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-1263.61%	Profit Margin	-439.48%	Rel Volume	0.96	Prev Close	31.45
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 07 BMO	Payout	-	Avg Volume	762.49K	Price	31.63
Recom	1.09	SMA20	4.47%	SMA50	12.82%	SMA200	37.68%	Volume	730,706	Change	0.57%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-08-23	Initiated	SVB Securities	Outperform	$33
May-24-23	Initiated	Goldman	Buy	$32
Apr-24-23	Upgrade	Stifel	Hold → Buy	$18 → $24
Mar-23-23	Initiated	Berenberg	Buy	$26
Feb-28-23	Initiated	RBC Capital Mkts	Outperform	$25
Dec-28-22	Initiated	CapitalOne	Overweight	$29
Oct-27-22	Initiated	Citigroup	Buy	$26
Aug-15-22	Downgrade	Stifel	Buy → Hold	$16 → $13
Jul-18-22	Resumed	Oppenheimer	Outperform	$25
Mar-10-22	Upgrade	Stifel	Hold → Buy	$27 → $20
Sep-23-21	Initiated	Stifel	Hold	$27
Jun-04-21	Resumed	Robert W. Baird	Outperform	$28
Mar-11-21	Initiated	Guggenheim	Buy	$32
Oct-07-20	Initiated	Wedbush	Outperform	$21
Sep-01-20	Initiated	Northland Capital	Outperform	$28
Jul-13-20	Upgrade	JP Morgan	Neutral → Overweight	$28
Jun-17-20	Reiterated	H.C. Wainwright	Buy	$13 → $22
Apr-06-20	Initiated	H.C. Wainwright	Buy	$13
Mar-13-20	Initiated	ROTH Capital	Buy	$12
Oct-17-19	Initiated	Oppenheimer	Outperform	$17

Show Previous Ratings

Nov-14-23 09:55AM	Can IDEAYA Biosciences, Inc. (IDYA) Climb 25.48% to Reach the Level Wall Street Analysts Expect? (Zacks)
Nov-07-23 07:15AM	IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
06:44AM	IDEAYA Biosciences Inc (IDYA) Reports Q3 2023 Financial Results and Business Update (GuruFocus.com)
06:00AM	IDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Nov-01-23 06:00AM	IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Jefferies London Healthcare Conference (PR Newswire) +6.33%
04:02PM	Loading…
Oct-27-23 04:02PM	IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire) -5.51%
06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Oct-25-23 11:55AM	Why Ideaya Biosciences Stock Is Plummeting Today (Motley Fool)
Oct-24-23 10:15PM	IDEAYA Announces Pricing of Public Offering (PR Newswire)
04:07PM	IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire)
Oct-23-23 06:00AM	IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Lethality Pipeline (PR Newswire) +5.54%
Oct-18-23 08:33AM	IDEAYA Biosciences, Inc. (IDYA) Surges 7.6%: Is This an Indication of Further Gains? (Zacks)
Oct-17-23 06:00AM	IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023 for Phase 2 Clinical Data Update for Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma (PR Newswire) +7.60%
Oct-16-23 06:00AM	IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanoma (PR Newswire)
Oct-09-23 06:00AM	IDEAYA Biosciences Announces Development Candidate Nomination of a Werner Helicase Inhibitor in Collaboration with GSK and Investor R&D Day (PR Newswire)
06:00AM	Loading…
Oct-06-23 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-27-23 06:00AM	IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast Cancer (PR Newswire)
Sep-26-23 06:00AM	IDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1/2 Mutations (PR Newswire)
Sep-15-23 01:03PM	Insider Sell: Chief Legal Officer Jason Throne Sells 1,000 Shares of IDEAYA Biosciences Inc (GuruFocus.com)
Sep-11-23 06:00AM	IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof-of-Concept for Potential First-in-Class PARG Inhibitor IDE161 in HRD Solid Tumors (PR Newswire)
Sep-05-23 06:00AM	IDEAYA Biosciences to Participate in Upcoming September 2023 Investor Relations Events (PR Newswire)
Aug-21-23 06:00AM	IDEAYA Biosciences Announces Clearance of IND Application for Pol Theta Helicase Development Candidate GSK101 (IDE705) (PR Newswire)
Aug-16-23 06:00AM	IDEAYA Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo)Adjuvant Uveal Melanoma (PR Newswire)
Aug-10-23 07:15AM	IDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
06:00AM	IDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Aug-08-23 10:02AM	DraftKings upgraded, Home Depot downgraded: Wall Street's top analyst calls (The Fly)
Aug-02-23 06:00AM	IDEAYA and Amgen Achieve First-Patient-In for Clinical Evaluation of IDE397 (MAT2A) and AMG 193 (PRMT5(MTA)) Combination in MTAP(-/-) Tumors (PR Newswire)
Aug-01-23 06:00AM	IDEAYA Biosciences to Participate in Upcoming August 2023 Investor Relations Event (PR Newswire)
Jul-28-23 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-30-23 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
06:00AM	Loading…
Jun-22-23 06:00AM	IDEAYA Announces First Reported Case of Uveal Melanoma Patient Spared Enucleation in Phase 1 Neoadjuvant IST with Darovasertib Monotherapy (PR Newswire)
Jun-12-23 06:00AM	IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types (PR Newswire)
Jun-11-23 09:56AM	Investors in IDEAYA Biosciences (NASDAQ:IDYA) have seen impressive returns of 223% over the past three years (Simply Wall St.)
May-30-23 06:00AM	IDEAYA Biosciences to Participate in Upcoming June 2023 Investor Relations Events (PR Newswire)
May-26-23 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-22-23 06:00AM	IDEAYA Announces IND Clearance Enabling Phase 1/2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP-Deletion Solid Tumors (PR Newswire)
May-16-23 06:00AM	IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma (PR Newswire)
May-09-23 07:25AM	IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +14.62%
06:00AM	IDEAYA Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
May-04-23 10:00AM	Will Entera Bio Ltd. (ENTX) Report Negative Q1 Earnings? What You Should Know (Zacks)
May-02-23 10:02AM	IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
May-01-23 06:00AM	IDEAYA Biosciences to Participate in Upcoming May 2023 Investor Relations Event (PR Newswire) +5.97%
Apr-29-23 09:00AM	Institutional investors are IDEAYA Biosciences, Inc.'s (NASDAQ:IDYA) biggest bettors and were rewarded after last week's US$297m market cap gain (Simply Wall St.)
Apr-28-23 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-27-23 04:01PM	IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Apr-25-23 05:44AM	Strength Seen in IDEAYA Biosciences, Inc. (IDYA): Can Its 35.7% Jump Turn into More Strength? (Zacks) -8.00%
12:15AM	IDEAYA Announces Pricing of Public Offering (PR Newswire)
Apr-24-23 04:12PM	IDEAYA Announces Proposed Public Offering of Common Stock (PR Newswire) +35.70%
12:13PM	IDEAYA Biosciences Touts Encouraging Data From Combo Therapy For Rare Eye Cancer Impacting Around 14,000 In US and Europe (Benzinga)
Apr-23-23 09:00AM	IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metastatic Uveal Melanoma (PR Newswire)
Apr-19-23 06:00AM	IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First-in-Class PARG Inhibitor Targeting HRD Solid Tumors (PR Newswire)
Apr-16-23 09:50AM	TipRanks Perfect 10 List: 2 Top-Rated Stocks Potentially Undervalued by ~90% (TipRanks)
Apr-03-23 06:00AM	IDEAYA Biosciences to Participate in Upcoming April 2023 Investor Relations Event (PR Newswire) +7.21%
Mar-31-23 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Mar-27-23 09:55AM	We Think IDEAYA Biosciences (NASDAQ:IDYA) Can Afford To Drive Business Growth (Simply Wall St.)
Mar-14-23 04:31PM	IDEAYA Announces Presentations at AACR Annual Meeting 2023 for Potential First-in-Class Synthetic Lethality Programs IDE397 (MAT2A), IDE161 (PARG) and Werner Helicase (PR Newswire)
Mar-07-23 07:15AM	IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +6.17%
06:00AM	IDEAYA Biosciences, Inc. Reports 2022 Financial Results and Provides Business Update (PR Newswire)
Mar-01-23 06:00AM	IDEAYA Biosciences to Participate in Investor Conferences in March 2023 (PR Newswire)
Feb-16-23 06:00AM	IDEAYA Biosciences to Participate in Citi's 2023 Virtual Oncology Leadership Summit (PR Newswire)
Feb-01-23 06:00AM	IDEAYA Biosciences to Participate in the 2023 Guggenheim Oncology Conference (PR Newswire)
Jan-23-23 06:00AM	IDEAYA Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma (PR Newswire) -7.15%
Jan-09-23 06:00AM	IDEAYA Announces IND Clearance by U.S. FDA enabling Phase 1 Initiation for First-in-Class PARG Development Candidate IDE161 (PR Newswire)
Jan-03-23 06:00AM	IDEAYA Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 (PR Newswire)
Jan-01-23 08:50AM	IDEAYA Biosciences (NASDAQ:IDYA) delivers shareholders splendid 28% CAGR over 3 years, surging 6.8% in the last week alone (Simply Wall St.)
Dec-19-22 06:00AM	IDEAYA Biosciences Appoints Dr. Karlene Cimprich, Ph.D. and Dr. Kornelia Polyak, M.D., Ph.D. to Scientific Advisory Board (PR Newswire)
Dec-12-22 06:00AM	IDEAYA Biosciences Announces Submission of IND Application to the U.S. FDA for PARG Development Candidate IDE161 (PR Newswire)
Dec-05-22 09:55AM	Wall Street Analysts Believe IDEAYA Biosciences, Inc. (IDYA) Could Rally 34%: Here's is How to Trade (Zacks)
06:00AM	IDEAYA Biosciences Receives Fast Track Designation for Darovasertib Combination Therapy with Crizotinib for the Treatment of Metastatic Uveal Melanoma (PR Newswire)
Nov-29-22 06:00AM	IDEAYA Biosciences Announces Agenda Topics and Key Opinion Leader Presenters for Investor R&D Day Webcast on Monday, December 12, 2022 (PR Newswire)
Nov-28-22 06:00AM	IDEAYA Biosciences Appoints Darrin M. Beaupre, M.D., Ph.D., as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline (PR Newswire) -5.97%
Nov-17-22 01:58PM	Alphabet Inc (GOOGL) Investment Portfolio: Top 15 Companies (Insider Monkey)
Nov-16-22 09:55AM	Wall Street Analysts Think IDEAYA Biosciences, Inc. (IDYA) Could Surge 32%: Read This Before Placing a Bet (Zacks)
Nov-10-22 05:02AM	IDEAYA Biosciences Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-08-22 07:35AM	IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings and Revenues Beat Estimates (Zacks)
06:00AM	IDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
Nov-01-22 06:00AM	IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Upcoming Investor Conferences (PR Newswire)
Oct-18-22 09:09AM	Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation (Simply Wall St.)
06:00AM	IDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In for Multiple Combination Cohorts in MTAP-Deletion Tumors (PR Newswire)
Sep-21-22 06:52AM	IDEAYA Biosciences, Inc. (NASDAQ:IDYA) has caught the attention of institutional investors who hold a sizeable 50% stake (Simply Wall St.)
Sep-19-22 04:01PM	IDEAYA Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire) +6.81%
Sep-14-22 10:41PM	IDEAYA Announces Pricing of Public Offering of Common Stock (PR Newswire)
04:39PM	IDEAYA Announces Proposed Public Offering of Common Stock (PR Newswire)
Sep-13-22 11:18AM	Ideaya (IDYA) Up on Interim Data from Mid-Stage Eye Cancer Study (Zacks)
Sep-12-22 01:22PM	IDEAYA Shares Jump On Positive Interim Data From Eye Cancer Trial (Benzinga) +30.70%
Sep-11-22 05:00PM	IDEAYA Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma (PR Newswire)
Sep-06-22 06:00AM	IDEAYA Announces First-Patient-In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in (Neo)Adjuvant Uveal Melanoma (PR Newswire)
Sep-04-22 11:08AM	The Market Bottom Is Near, Says Oppenheimer Here Are 2 Stocks to Play That Bullish Sentiment (TipRanks)
Aug-30-22 06:00AM	IDEAYA Biosciences to Participate in Investor Conferences in September 2022 (PR Newswire)
Aug-29-22 10:28AM	IDEAYA Achieves First Milestone In GSK Pact For Pol Theta Helicase Inhibitor Candidate (Benzinga)
06:00AM	IDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First-in-Class Pol Theta Helicase Inhibitor Development Candidate (PR Newswire)
Aug-25-22 06:05AM	The IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Analysts Have Been Trimming Their Sales Forecasts (Simply Wall St.)
Aug-15-22 01:17PM	Why IDEAYA Biosciences Shares Plunging Today (Benzinga) -34.82%
07:15AM	IDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
06:00AM	IDEAYA Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
Aug-02-22 10:00AM	IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-27-22 10:35AM	IDEAYA's Cancer Candidate Shows Early Tumor Modulation (Benzinga)
06:05AM	IDEAYA Announces IDE397 Clinical Program Update and ctDNA Molecular Responses Demonstrating Tumor Pharmacodynamic Modulation (PR Newswire)
06:00AM	IDEAYA Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors (PR Newswire)
Jul-25-22 07:42AM	Investing in IDEAYA Biosciences (NASDAQ:IDYA) three years ago would have delivered you a 120% gain (Simply Wall St.)

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Throne Jason	Chief Legal Officer	Nov 03	Option Exercise	12.86	5,163	66,396	5,163	Nov 07 05:47 PM
Throne Jason	Chief Legal Officer	Nov 03	Sale	30.09	5,163	155,360	0	Nov 07 05:47 PM
Throne Jason	Chief Legal Officer	Sep 12	Option Exercise	12.86	1,000	12,860	1,000	Sep 14 05:23 PM
Throne Jason	Chief Legal Officer	Sep 12	Sale	30.00	1,000	30,005	0	Sep 14 05:23 PM
Throne Jason	Chief Legal Officer	Sep 05	Option Exercise	12.86	1,737	22,338	1,737	Sep 06 06:37 PM
Throne Jason	Chief Legal Officer	Sep 05	Sale	30.03	1,737	52,160	0	Sep 06 06:37 PM
Throne Jason	Chief Legal Officer	Sep 01	Option Exercise	12.86	2,100	27,006	2,100	Sep 06 06:37 PM
Throne Jason	Chief Legal Officer	Sep 01	Sale	30.03	2,100	63,063	0	Sep 06 06:37 PM
Ruiz Briseno Andres	See Remarks	Sep 01	Sale	30.01	2,000	60,016	32,531	Sep 06 06:36 PM
Stone Paul A.	Chief Financial Officer	Aug 29	Sale	28.87	5,000	144,352	9,303	Aug 31 05:49 PM
Stone Paul A.	Chief Financial Officer	Aug 21	Sale	26.40	978	25,819	14,303	Aug 23 06:31 PM
Stone Paul A.	Chief Financial Officer	Aug 18	Sale	26.38	3,822	100,820	15,281	Aug 18 06:33 PM
Stone Paul A.	Chief Financial Officer	Aug 16	Sale	26.43	200	5,285	19,103	Aug 18 06:33 PM
Throne Jason	Chief Legal Officer	Aug 09	Option Exercise	13.34	5,000	66,700	5,000	Aug 11 07:22 PM
Throne Jason	Chief Legal Officer	Aug 09	Sale	25.09	5,000	125,430	0	Aug 11 07:22 PM
Stone Paul A.	Chief Financial Officer	Aug 09	Sale	25.05	2,500	62,613	19,303	Aug 11 07:21 PM
Throne Jason	Chief Legal Officer	Jul 10	Option Exercise	10.09	9,485	95,740	9,485	Jul 12 05:25 PM
Throne Jason	Chief Legal Officer	Jul 10	Sale	23.00	9,485	218,178	0	Jul 12 05:25 PM
Throne Jason	Chief Legal Officer	Jun 01	Option Exercise	7.01	3,553	24,907	3,553	Jun 02 05:29 PM
Throne Jason	Chief Legal Officer	Jun 01	Sale	23.02	3,553	81,792	0	Jun 02 05:29 PM
Throne Jason	Chief Legal Officer	May 31	Option Exercise	7.01	432	3,028	432	Jun 02 05:29 PM
Throne Jason	Chief Legal Officer	May 31	Sale	23.00	432	9,938	0	Jun 02 05:29 PM
Throne Jason	Chief Legal Officer	May 22	Option Exercise	7.01	500	3,505	500	May 24 05:51 PM
Throne Jason	Chief Legal Officer	May 22	Sale	23.00	500	11,500	0	May 24 05:51 PM
Stone Paul A.	Chief Financial Officer	Apr 13	Option Exercise	4.62	8,000	36,960	21,803	Apr 14 01:20 PM
Hata Yujiro S	President and CEO	Apr 12	Option Exercise	4.31	11,601	50,000	677,887	Apr 13 04:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IDYA

Ideaya Biosciences Inc

Upgrade your FINVIZ experience